Germany as a location for pharmaceutical businesses - quo vadis, 2024?
Strategy paper by the German Federal Government on improving the regulatory framework for the pharmaceutical industry in Germany
by Dr. Manja Epping and Irina Rebin
Current developments in the field of clinical drug trials in Germany - adjusting parameters to shorten procedures before the start of a clinical trial
OLG Brandenburg: Infringement of the price fixing for prescription-only medicinal products through granting cash discount for prompt payment
German Bundesrat passes the law to reduce supply shortages of medicinal products
Personalised medicines and exclusive protection
The EU Commission's new pharmaceutical package: amended legal framework for data protection, marketing protection and market exclusivity
by Dr. Manja Epping and Sherin Sayed
The CJEU: The recurring question of the separation of medicinal products and medical devices
by Dr. Manja Epping and Sherin Sayed
New Competition Rules for R&D Cooperation Agreements
by Stephan Manuel Nagel, LL.M. (EUI) and Dr. Nora E. Wessendorf, LL.M. (Washington)
Higher Regional Court of Hamm on the advertising ban in Sec. 12 HWG in the context of the COVID 19 pandemic
Long-running issue: the distinction between cosmetic products and medicinal products by function
by Dr. Manja Epping and Sherin Sayed
Federal Social Court: High barriers for cannabis on health insurance prescription
OLG Frankfurt am Main: Distribution of free drug samples to pharmacists